You are here

IGF::OT::IGF : Novel Treatment for Drug-induced Respiratory Depression. September 18, 2014 - March 17, 2014. N01DA-14-2239.

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43DA140065
Agency Tracking Number: N43DA140065
Amount: $148,583.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDA
Solicitation Number: N/A
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
325 GREENWAY ROAD
RIDGEWOOD, NJ 99999-
United States
DUNS: 032659263
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ARNOLD LIPPA
 ALIPPA@CORTEXPHARM.COM
Business Contact
 ARNOLD LIPPA
Email: ALIPPA@CORTEXPHARM.COM
Research Institution
 Stub
Abstract

Using plethysmographic measurements in various groups of rats, the proposed studies will determine the potency, latency to onset and duration of action of CX1942 when adminisstered either prior to, simultaneously with or subsequent to administration of either an opiate (morphine or fentanyl), a benzodiazepine (diazeman or alprazolam) in combination with an opiate or a benzodiazepine in combination with ethanol. PUBLIC HEALTH RELEVANCE

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government